ArticleJournal of pediatric gastroenterology and nutrition2026
Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesNonesophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are rare, underrecognized inflammatory diseases of the gastrointestinal (GI) tract, especially in children. Their clinical heterogeneity and lack of specific biomarkers contribute to diagnostic delays and therapeutic challenges.
methodsThis retrospective multicenter study included pediatric patients (<18 years) diagnosed with non-EoE EGIDs across 12 Italian centers affiliated with the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition (SIGENP). The data were retrospectively collected from January 2012 to December 2022. Diagnosis was based on ESPGHAN histological criteria. Clinical, laboratory, endoscopic, and histological data were collected at baseline and during follow-up. Treatment modalities and outcomes were analyzed.
resultsA total of 86 patients (71% male; median age 10.5 years) were included. The stomach was the most commonly involved site (45.4%), followed by the small bowel (40.7%) and colon (24.4%). Multiple segment involvement occurred in 45.4% of cases. Abdominal pain (64.9%) and diarrhea (38.2%) were the most common symptoms, with diarrhea significantly associated with colonic involvement. Laboratory findings showed peripheral eosinophilia in 50% of patients and hypoalbuminemia in those with multisegment involvement. Very early-onset EGIDs (>1 and <2 years) were associated with features such as predominant colonic involvement and anemia. Treatment responses varied: 50% achieved clinical remission after first-line therapy (proton pump inhibitors, topical/systemic steroids, or elimination diets). Among 61/86 patients who underwent endoscopic follow-up, 49.2% achieved macroscopic remission and 40.9% histological remission.
conclusionsPediatric non-EoE EGIDs present with heterogeneous symptoms and variable tract involvement. Younger children show distinct phenotypes. Laboratory findings are nonspecific and have limited diagnostic utility. Treatment remains challenging, with suboptimal response rates. These findings underscore the need for prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.